Shares of Novavax, Inc.(Public, NASDAQ:NVAX) continue to rise to $3.00 +0.32 (11.94%) as news of the World Health Organization's increased concern over an "Imminent" Flu Pandemic continues to make headlines. Novavax, with it's VLP technology, was one of the firms mentioned in our Flu Vaccine Initiative report (05/25/08). The other company in that report is Hemispherx BioPharma, Inc (AMEX:HEB)- a loser today- whose shares continue to float in oblivion as the FDA has yet to report whether HEB's Ampligen drug has received approval for CFS. Shares were down (-11.27%) minus $0.32 to $2.52. The company is waiting for more information just like the shareholders.
$3.0 (06/11/09)
